CoChat

p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775

Open access
Hauge, Sissel, Macurek, Libor, Syljuåsen, Randi G. · 2019 · Cell Cycle

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21 (HCT116 p21-/-, RPE p21-/-, and U2OS transfected with p21 siRNA) showed higher induction of the DNA damage marker γH2AX in S-phase in response to MK1775 compared to the respective parental cells. Furthermore, upon MK1775 treatment the levels of phospho-DNA PKcs S2056 and phospho-RPA S4/S8 were higher in the p21 deficient cells, consistent with increased DNA breakage. Cell cycle analysis revealed that these effects were due to an S-phase function of p21, but MK1775-induced S-phase CDK activity was not altered as measured by CDK-dependent phosphorylations. In the p21 deficient cancer cells MK1775-induced cell death was also increased. Moreover, p21 deficiency sensitized to combined treatment of MK1775 and the CHK1-inhibitor AZD6772, and to the combination of MK1775 with ionizing radiation. These results show that p21 protects cancer cells against Wee1 inhibition and suggest that S-phase functions of p21 contribute to mediate such protection. As p21 can be epigenetically downregulated in human cancer, we propose that p21 levels may be considered during future applications of Wee1 inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15384101.2019.1593649

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. p21 deficiency causes increased DNA damage in S phase after Wee1 inhibition. (a). Immunoblot analysis showing p21 knockdown efficiency in U2OS cells, and confirming p21 knockout in HCT116 and RPE cells. U2OS cells were harvested 48 hours after transfection with p21 siRNA. The two first lanes in the U2OS blot were loaded with 10% and 25% of the mock transfected sample (NT). HCT116 wt/p21-/- and RPE wt/p21-/- cells were irradiated with 6 Gy and harvested after 4 hours. CDK1 or Actin were used as loading controls. (b). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected), HCT116 wt/p21-/- and RPE wt/p21-/- cells treated for 24 hours with MK1775. Scatter plots of γH2AX versus Hoechst (DNA) and the corresponding DNA histograms are shown from representative experiments. Numbers are the percentage of cells within the indicated region with strong γH2AX signal (red color). The graphs to the right show the mean percentage of cells with strong γH2AX signals. Error bars: SEM (N ≥ 3).*P < 0,05. (c). Immunoblot analysis showing double strand break signaling in U2OS (mock (NT) or p21 siRNA transfected), HCT116 wt/p21-/- and RPE wt/p21-/- cells after 24 hours of MK1775 treatment at the indicated concentrations.
Figure 1. p21 deficiency causes increased DNA damage in S phase after Wee1 inhibition. (a). Immunoblot analysis showing p21 knockdown efficiency in U2OS cells, and confirming p21 knockout in HCT116 and RPE cells. U2OS cells were harvested 48 hours after transfection with p21 siRNA. The two first lanes in the U2OS blot were loaded with 10% and 25% of the mock transfected sample (NT). HCT116 wt/p21-/- and RPE wt/p21-/- cells were irradiated with 6 Gy and harvested after 4 hours. CDK1 or Actin were used as loading controls. (b). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected), HCT116 wt/p21-/- and RPE wt/p21-/- cells treated for 24 hours with MK1775. Scatter plots of γH2AX versus Hoechst (DNA) and the corresponding DNA histograms are shown from representative experiments. Numbers are the percentage of cells within the indicated region with strong γH2AX signal (red color). The graphs to the right show the mean percentage of cells with strong γH2AX signals. Error bars: SEM (N ≥ 3).*P < 0,05. (c). Immunoblot analysis showing double strand break signaling in U2OS (mock (NT) or p21 siRNA transfected), HCT116 wt/p21-/- and RPE wt/p21-/- cells after 24 hours of MK1775 treatment at the indicated concentrations.CC BY-NC-ND · PubMed Central
Figure 2. The increased DNA damage in p21 deficient cells occurs specifically in S phase, but is not caused by elevated CDK activity. (a). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected) and RPE (wt/p21-/-) cells treated with MK1775 (20 hours with 300nM and 24 hours with 1μM, respectively) and Nocodazole simultaneously. Scatter plots of γH2AX versus Hoechst (DNA) are shown from representative experiments. Numbers are the percentage of cells within the indicated region with strong γH2AX signal (red color). (b). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected) and HCT116 wt/p21-/- cells treated as shown in the work flow at the top. The S-phase population was first labeled with a short EdU pulse, and then cells were washed and treated with 1μM MK1775 (MK1775) or left untreated (Mock). At 6 or 10 hours later (for U2OS and HCT116 cells, respectively), samples were fixed and stained for γH2AX, EdU and DNA content. Scatter plots showing γH2AX versus FxCycle (DNA) for EdU positive cells, are presented in the top row. Numbers are the percentage of cells within the indicated region with strong γH2AX signal (red color). Associated DNA histograms of EdU positive cells are shown in the bottom row. Note that the scatter plots and DNA histograms include only the EdU positive cells (which were in S phase 6 or 10 hours earlier). (c and d). Flow cytometric analysis of CDK-dependent phosphorylations in S phase cells. U2OS cells mock transfected (NT) or transfected with p21 siRNA, HCT116 wt/p21-/- and RPE wt/p21-/- cells were treated with 1μM MK1775 for 90 minutes, or left untreated (Mock). Samples were bar-coded with Pacific Blue before antibody staining with the indicated antibodies. Scatter plots of phospho-B-Myb (T487), phospho-Ser/Thr-Pro MPM-2 and phospho-BRCA2 (S3291) versus FxCycle (DNA) shown in C., are from a representative experiment in the HCT116 isogenic cell system. S-phase cells are indicated in dark color, and numbers are median signal values in the S phase gates, with background signals subtracted. Graphs in D. show average median values in S-phase (relative to Mock) for all cell lines. Error bars: SEM (N = 3 (2 in HCT116 cells)).
Figure 2. The increased DNA damage in p21 deficient cells occurs specifically in S phase, but is not caused by elevated CDK activity. (a). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected) and RPE (wt/p21-/-) cells treated with MK1775 (20 hours with 300nM and 24 hours with 1μM, respectively) and Nocodazole simultaneously. Scatter plots of γH2AX versus Hoechst (DNA) are shown from representative experiments. Numbers are the percentage of cells within the indicated region with strong γH2AX signal (red color). (b). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected) and HCT116 wt/p21-/- cells treated as shown in the work flow at the top. The S-phase population was first labeled with a short EdU pulse, and then cells were washed and treated with 1μM MK1775 (MK1775) or left untreated (Mock). At 6 or 10 hours later (for U2OS and HCT116 cells, respectively), samples were fixed and stained for γH2AX, EdU and DNA content. Scatter plots showing γH2AX versus FxCycle (DNA) for EdU positive cells, are presented in the top row. Numbers are the percentage of cells within the indicated region with strong γH2AX signal (red color). Associated DNA histograms of EdU positive cells are shown in the bottom row. Note that the scatter plots and DNA histograms include only the EdU positive cells (which were in S phase 6 or 10 hours earlier). (c and d). Flow cytometric analysis of CDK-dependent phosphorylations in S phase cells. U2OS cells mock transfected (NT) or transfected with p21 siRNA, HCT116 wt/p21-/- and RPE wt/p21-/- cells were treated with 1μM MK1775 for 90 minutes, or left untreated (Mock). Samples were bar-coded with Pacific Blue before antibody staining with the indicated antibodies. Scatter plots of phospho-B-Myb (T487), phospho-Ser/Thr-Pro MPM-2 and phospho-BRCA2 (S3291) versus FxCycle (DNA) shown in C., are from a representative experiment in the HCT116 isogenic cell system. S-phase cells are indicated in dark color, and numbers are median signal values in the S phase gates, with background signals subtracted. Graphs in D. show average median values in S-phase (relative to Mock) for all cell lines. Error bars: SEM (N = 3 (2 in HCT116 cells)).CC BY-NC-ND · PubMed Central
Figure 3. Effects of p21 status on mitotic entry and G1/S arrest after Wee1 inhibition. (a). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected), HCT116 wt/p21-/- and RPE wt/p21-/- cells treated for 24 hours with MK1775 at the indicated concentrations. Scatter plots of phospho-Histone H3 (S10) versus Hoechst (DNA) are shown from representative experiments. Numbers are the percentage of cells within the indicated region of mitosis (in black). (b). The mean percentage of mitotic cells after indicated MK1775 concentrations and time-points, from experiments analyzed as in A. Of note, for the 90 minutes time-points, mitotic cells were measured by phospho-B-Myb (T487). Error bars: Standard error of mean (SEM) (N = 2–3). (c). Scatter plots of γH2AX versus Hoechst (DNA), and phospho-Histone H3 (S10) versus Hoechst (DNA) from the same experiments as in A. The cells with strong γH2AX signal (red color) are also shown in red in the phospho-Histone H3 plots. (d). U2OS (mock (NT) or p21 siRNA transfected), HCT116 wt/p21-/- and RPE wt/p21-/- cells were mock treated or treated for 24 hours with Nocodazole alone or Nocodazole and MK1775 (300nM in U2OS, 600nM in HCT116 and 1μM in RPE cell systems). Samples were analyzed by flow cytometry, and the histograms show the DNA profiles of representative experiments. (e). Cells were treated for 24 hours with MK1775 (300nM, 600nM and 1μM, respectively) and fixed (top row) or washed and subsequently grown for 24 additional hours in the presence of Nocodazole (bottom row). Arrows in the bottom panels indicate where cells arrested at a second cycle G1 checkpoint would be present.
Figure 3. Effects of p21 status on mitotic entry and G1/S arrest after Wee1 inhibition. (a). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected), HCT116 wt/p21-/- and RPE wt/p21-/- cells treated for 24 hours with MK1775 at the indicated concentrations. Scatter plots of phospho-Histone H3 (S10) versus Hoechst (DNA) are shown from representative experiments. Numbers are the percentage of cells within the indicated region of mitosis (in black). (b). The mean percentage of mitotic cells after indicated MK1775 concentrations and time-points, from experiments analyzed as in A. Of note, for the 90 minutes time-points, mitotic cells were measured by phospho-B-Myb (T487). Error bars: Standard error of mean (SEM) (N = 2–3). (c). Scatter plots of γH2AX versus Hoechst (DNA), and phospho-Histone H3 (S10) versus Hoechst (DNA) from the same experiments as in A. The cells with strong γH2AX signal (red color) are also shown in red in the phospho-Histone H3 plots. (d). U2OS (mock (NT) or p21 siRNA transfected), HCT116 wt/p21-/- and RPE wt/p21-/- cells were mock treated or treated for 24 hours with Nocodazole alone or Nocodazole and MK1775 (300nM in U2OS, 600nM in HCT116 and 1μM in RPE cell systems). Samples were analyzed by flow cytometry, and the histograms show the DNA profiles of representative experiments. (e). Cells were treated for 24 hours with MK1775 (300nM, 600nM and 1μM, respectively) and fixed (top row) or washed and subsequently grown for 24 additional hours in the presence of Nocodazole (bottom row). Arrows in the bottom panels indicate where cells arrested at a second cycle G1 checkpoint would be present.CC BY-NC-ND · PubMed Central
Figure 4. p21 protects cancer cells against Wee1 inhibition induced cell death. (a and b). U2OS cells mock transfected (NT) or transfected with p21 siRNA, and HCT116 wt/p21-/- cells were treated with the indicated concentrations of MK1775 for 24 hours. The cells were then either fixed, or washed and then left in fresh medium for three additional days before fixation. Pacific Blue (PB) staining was performed before fixation in order to distinguish viable (PB negative) from non-viable (PB-positive) cells. After staining for DNA content, analysis was performed by flow cytometry. The scatter plots of Pacific Blue versus side scatter presented in A. show a representative experiment from the HCT116 cell line. Numbers indicate the percentage of PB positive cells. The graphs in B. show the mean percentage of PB positive cells after the indicated treatments. Error bars: SEM (N = 3 (2 in HCT116 cells “1μM 24h + 3 days”)). *P < 0,05. (c and d). Calculations of the sub-G1 population in the same experiments as in A and B. DNA histograms in C. show a representative experiment from the HCT116 cell line. Numbers indicate the percentage of cells in the sub-G1 gate. The graphs in D. show the mean percentage of sub-G1 cells after the indicated treatments. Error bars: SEM. (e). Viability of U2OS (mock or p21 siRNA transfected), and HCT116 wt/p21-/- cells, measured by the RealTimeGlo (U2OS) or CellTiterGlo (HCT116) assays at 4 and 6 days, respectively, after addition of MK1775 at the indicated concentrations. Error bars: SEM (N = 3). (f). Clonogenic survival assay of HCT116 wt and p21-/- cells treated with MK1775 at the indicated concentrations for 24 hours. Results shown are from one representative experiment. Error bars: standard deviation of three parallel dishes. (g). Average survival fractions of p21 deficient relative to p21 proficient cells from three independent experiments in U2OS and HCT116 cells performed as in F. The ratios of survival fractions for p21 siRNA transfected U2OS cells relative to mock, and for HCT116 p21-/- cells relative to wt cells, are shown. Error bars: SEM (N = 3 except for HCT116 cells with 1μM MK1775 (N = 2)).
Figure 4. p21 protects cancer cells against Wee1 inhibition induced cell death. (a and b). U2OS cells mock transfected (NT) or transfected with p21 siRNA, and HCT116 wt/p21-/- cells were treated with the indicated concentrations of MK1775 for 24 hours. The cells were then either fixed, or washed and then left in fresh medium for three additional days before fixation. Pacific Blue (PB) staining was performed before fixation in order to distinguish viable (PB negative) from non-viable (PB-positive) cells. After staining for DNA content, analysis was performed by flow cytometry. The scatter plots of Pacific Blue versus side scatter presented in A. show a representative experiment from the HCT116 cell line. Numbers indicate the percentage of PB positive cells. The graphs in B. show the mean percentage of PB positive cells after the indicated treatments. Error bars: SEM (N = 3 (2 in HCT116 cells “1μM 24h + 3 days”)). *P < 0,05. (c and d). Calculations of the sub-G1 population in the same experiments as in A and B. DNA histograms in C. show a representative experiment from the HCT116 cell line. Numbers indicate the percentage of cells in the sub-G1 gate. The graphs in D. show the mean percentage of sub-G1 cells after the indicated treatments. Error bars: SEM. (e). Viability of U2OS (mock or p21 siRNA transfected), and HCT116 wt/p21-/- cells, measured by the RealTimeGlo (U2OS) or CellTiterGlo (HCT116) assays at 4 and 6 days, respectively, after addition of MK1775 at the indicated concentrations. Error bars: SEM (N = 3). (f). Clonogenic survival assay of HCT116 wt and p21-/- cells treated with MK1775 at the indicated concentrations for 24 hours. Results shown are from one representative experiment. Error bars: standard deviation of three parallel dishes. (g). Average survival fractions of p21 deficient relative to p21 proficient cells from three independent experiments in U2OS and HCT116 cells performed as in F. The ratios of survival fractions for p21 siRNA transfected U2OS cells relative to mock, and for HCT116 p21-/- cells relative to wt cells, are shown. Error bars: SEM (N = 3 except for HCT116 cells with 1μM MK1775 (N = 2)).CC BY-NC-ND · PubMed Central
Figure 5. Lack of p21 sensitizes cancer cells to combined treatment with Wee1 and Chk1 inhibitors and to the combination of Wee1 inhibition and ionizing radiation. (a). Viability of U2OS (mock or p21 siRNA transfected), and HCT116 wt/p21-/- cells, measured by the RealTimeGlo (U2OS) or CellTiterGlo (HCT116) assays at 4 and 6 days, respectively, after addition of AZD7762 at the indicated concentrations. Error bars: SEM (N = 3 (2 in HCT116 cells 100nM AZD7762)). (b). Viability measured as in A. after addition of MK1775 and AZD7762 at the indicated concentrations. Error bars: SEM (N = 3 (2 in HCT116 cells 100nM AZD7762)). (c). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected) and HCT116 wt/p21-/- cells treated for 24 hours with the Wee1 inhibitor MK1775, the CHK1 inhibitor AZD7762, or the combination of both, in indicated concentrations. Scatter plots of γH2AX versus Hoechst (DNA) are shown from representative experiments. Numbers are the percentage of cells within the indicated region with strong γH2AX signal (red color). (d). Top histograms: Viability of U2OS (mock or p21 siRNA transfected), and HCT116 wt/p21-/- cells, measured by the RealTimeGlo (U2OS) or CellTiterGlo (HCT116) assays at 4 and 6 days, respectively, after treatment with MK1775 in the indicated concentrations and X-ray irradiation (2 Gy). Viability was calculated relative to the corresponding non-irradiated p21 proficient or defective sample (such as in Figure 4E). Bottom graphs: Viability was calculated relative to the 2Gy but otherwise untreated samples, for p21 positive and negative cells respectively. Error bars: SEM (N = 3).
Figure 5. Lack of p21 sensitizes cancer cells to combined treatment with Wee1 and Chk1 inhibitors and to the combination of Wee1 inhibition and ionizing radiation. (a). Viability of U2OS (mock or p21 siRNA transfected), and HCT116 wt/p21-/- cells, measured by the RealTimeGlo (U2OS) or CellTiterGlo (HCT116) assays at 4 and 6 days, respectively, after addition of AZD7762 at the indicated concentrations. Error bars: SEM (N = 3 (2 in HCT116 cells 100nM AZD7762)). (b). Viability measured as in A. after addition of MK1775 and AZD7762 at the indicated concentrations. Error bars: SEM (N = 3 (2 in HCT116 cells 100nM AZD7762)). (c). Flow cytometric analysis of U2OS (mock (NT) or p21 siRNA transfected) and HCT116 wt/p21-/- cells treated for 24 hours with the Wee1 inhibitor MK1775, the CHK1 inhibitor AZD7762, or the combination of both, in indicated concentrations. Scatter plots of γH2AX versus Hoechst (DNA) are shown from representative experiments. Numbers are the percentage of cells within the indicated region with strong γH2AX signal (red color). (d). Top histograms: Viability of U2OS (mock or p21 siRNA transfected), and HCT116 wt/p21-/- cells, measured by the RealTimeGlo (U2OS) or CellTiterGlo (HCT116) assays at 4 and 6 days, respectively, after treatment with MK1775 in the indicated concentrations and X-ray irradiation (2 Gy). Viability was calculated relative to the corresponding non-irradiated p21 proficient or defective sample (such as in Figure 4E). Bottom graphs: Viability was calculated relative to the 2Gy but otherwise untreated samples, for p21 positive and negative cells respectively. Error bars: SEM (N = 3).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 48 references

Cited by

See all 30

Metadata

Authors
Hauge, S., Macurek, L., & Syljuåsen, R. G.
Affiliations
  • Oslo University Hospital (NO)
  • Department of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic
Corresponding author
Syljuåsen, Randi G.
Venue
Cell Cycle
Published
2019-04-03
Volume
18
Issue
8
Pages
834-847
ISSN
  • 1538-4101 (ISSN-L)
  • 1551-4005
OpenAlex
W2929688087
Cited by
30
References
48
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 6 · 2022: 6 · 2021: 2 · 2020: 5 · 2019: 2
FWCI
1.57
Type
journal article
Language
en
Open access
Locations
  • Cell Cycle (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Helse Sør-Øst RHF (2016114)
  • Kreftforeningen (62320, 198018)
  • Grant Agenzy of the Czech Republic (17-04742S)
  • EEA Czexg-Norwegian Research Programme (7F14061)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
Keywords
p21, MK-1775, AZD1775, WEE1 inhibitor, S phase, DNA damage, γH2AX, CDK inhibition, DNA double-strand breaks, DNA-PKcs, RPA, p53 target genes, cell death, CHK1 inhibitor, ionizing radiation, cancer therapy
MeSH terms
Checkpoint Kinase 1, Antineoplastic Agents, Cell Survival, DNA Damage, Humans, Neoplasms, Phosphorylation, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidinones, Transfection, Cell Cycle Proteins, Cyclin-Dependent Kinases, RNA, Small Interfering, HCT116 Cells, Cyclin-Dependent Kinase Inhibitor p21, S Phase Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775. https://app.cochat.ai/papers/10.1080/15384101.2019.1593649
The paper
Hauge, S., Macurek, L., & Syljuåsen, R. G. (2019). p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775. Cell Cycle. https://doi.org/10.1080/15384101.2019.1593649

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.